EMA Might Not Decide On Merck’s COVID-91 Oral Antiviral Before Christmas: Reuters
The EU drug regulator might not decide whether to approve Merck & Co Inc's (NYSE: MRK) molnupiravir, COVID-19 antiviral until after Christmas, a source with knowledge of the matter said,
Gilead’s Kite, Daiichi Sankyo Report Authorized First YESCARTA CAR T-Cell Therapy Treatment Site In Japan
-- Kite and Daiichi Sankyo to Expand YESCARTA® Collaboration in Japan --
SANTA MONICA, Calif. & TOKYO--(BUSINESS WIRE)-- Kite, a Gilead Company, and Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo)
Gilead’s CAR-T Yescarta Shows 78% Complete Response Rate In First-Line Lymphoma Patients
Kite Pharma, a Gilead Science Inc company (NASDAQ: GILD),
Gilead’s Kite Unveils More Data On Yescarta In Second-Line Lymphoma Patients
Kite Pharma, a Gilead Science Inc's Company (NASDAQ: GILD), announced
Gilead’s Kite Announced Yescarta Is First CAR T-cell Therapy to Report Five-Year Survival Data From Pivotal Study Showing Durable Long-Term Survival in Patients With Refractory Large B-cell Lymphoma; Said 42.6% of Study Patients Alive at Five Years Fol…
Kite, a Gilead Company (Nasdaq: GILD), today announced five-year follow-up data from the pivotal ZUMA-1 trial of Yescarta® (axicabtagene ciloleucel) in adult patients with refractory large B-cell lymphoma (LBCL).
‘House Democrats find in three-year investigation that drug prices are ‘unsustainable, unjustifiable and unfair” -Washington Post
https://www.washingtonpost.com/health/2021/12/10/house-democrats-find-three-ye
Gilead Reports Trodelvy Showed Clinical Benefit For Black Patients Consistent With Full Metastatic Triple-Negative Breast Cancer Population In ASCENT Study
Disparities, Such as Access to Healthcare, Comorbidities and Differences in TNBC Disease Biology Typically Drive Worse Clinical Outcomes in Black Women –
FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences,
Benzinga’s Top Ratings Upgrades, Downgrades For December 9, 2021
Upgrades
According to BMO Capital, the prior rating for Nuvei Corp (NASDAQ:NVEI) was changed from Market Perform to Outperform.
Wells Fargo Initiates Coverage On Gilead Sciences with Equal-Weight Rating, Announces Price Target of $72
Wells Fargo analyst Mohit Bansal initiates coverage on Gilead Sciences (NASDAQ:GILD) with a Equal-Weight rating and announces Price Target of $72.